RxDoctor Payments Data

Micaela Chatman, MD

Neurology · Roseville, MNNPI 1902067002

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $150 of the $167 with a category attached, or 90.0%. Medtronic accounts for 75.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $126 and has fallen 86.8% since, to $17 in 2024.

$167in general payments, 2019–2025

Across 3 payments — averaging $55.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$126
  • UCB, Inc.$23
  • Catalyst Pharmaceuticals, Inc.$17
$193,543in research payments, 2019–2025

Across 33 payments — averaging $5864.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • UCB SA$137K
  • Aquestive Therapeutics, Inc.$44K
  • UCB, Inc.$13K

What the payments were for

  • Food & beverage$15090%
  • Education$1710%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic1$126
UCB, Inc.1$23
Catalyst Pharmaceuticals, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$167 in reported general payments places this provider in the 55th percentile of 434 neurology providers in Minnesota.

See all neurology providers in Minnesota

Medicare billing

Part B allowed, 2024
$42,124
Medicare patients
143
Services billed
277

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam138$278,784
EpidiolexCannabidiol (Cbd)25$221,871
OnfiClobazam13$62,040
Felbamate129$48,170
Rufinamide28$47,616
AptiomEslicarbazepine Acetate15$44,341
LamictalLamotrigine19$38,604
FycompaPerampanel25$30,244
Lacosamide162$19,275
Levetiracetam356$17,923
Lamotrigine297$10,357
Clobazam53$6,986
Oxcarbazepine92$6,798
Lamotrigine ErLamotrigine13$5,300
Divalproex Sodium ErDivalproex Sodium111$5,209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$23$278,784138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 434 neurology providers in Minnesota.

Other neurology in Roseville

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →